Company intelligence / Profile preview
L2 Bio
Henderson, Nevada, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
L2 Bio has secured FDA approval to initiate a Phase 2b clinical trial evaluating intravenous autologous/familial adipose-derived mesenchymal stem cells in Crohn's Disease. Early descriptions emphasize high safety, personalized matching, and minimal side effects. The procedure enables rapid cell isolation for durable therapy, but clinical efficacy data have not yet been published.[1][2][7]
- Therapeutic areas
- Gastroenterology
- Modalities
- Cell therapyAdipose-derived mesenchymal stem cellsAutologous stem cells
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on L2 Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on L2 Bio.